An association between certain vaccinations and onset or relapse of multiple sclerosis (MS) has been debated. Based on PubMed, we made a thorough literature review and included all relevant studies, 51 on MS and 15 on optic neuritis (ON). Case studies were excluded. With the exception of a live vaccine against yellow fever, vaccinations appear safe in untreated patients with MS and ON. However, most studies were underpowered, and small risks cannot be excluded. One study of BCG vaccination after the first demyelinating event showed even a reduced risk of developing MS. Further studies are needed to fully exclude a causal association. The objective of this review is to investigate the following:
| INTRODUCTION
Currently, immunization through vaccination is one of the most effective ways to prevent potentially deadly infections. Multiple sclerosis (MS) is a chronic disease, which is thought to be caused by immunemediated demyelination of the central nervous system. However, as the aetiology and pathophysiology of MS are not fully understood, a varying but small number of cases of MS following vaccination gave rise to speculation of a possible causal relationship. The public attitude towards vaccination has great impact on compliance as illustrated by the drop in HBV (hepatitis B) mass vaccine coverage following reports of a temporal association of the vaccine and MS onset, but later followed by a series of negative studies. 1, 2 This underlines the importance of summarizing results of epidemiological studies in order to not confuse temporal and causal association. For example, those offered HPV vaccination are mainly young women, thus the same group with the relatively highest risk of developing MS or optic neuritis (ON), an onset symptom in 20% of patients with MS. 3 In weighing the potential advantages and disadvantages of vaccines, one should remember that in patients with MS, vaccines are able to prevent some infections known to increase the risk of relapses or pseudo-relapses. 4 The objective of this review is to investigate the following:
• The potential role of vaccines as a predisposing factor for the development of MS or ON.
• Influence of vaccines on the risk of relapses in MS.
• Beneficial and damaging effect of vaccines on patients with MS or ON.
Caveat: The relation between vaccination and various diseasemodifying drugs used in MS is outside the scope of this comprehensive review.
| METHODS
A complete literature review based on PubMed and search criteria with major MeSH words MS, vaccines, vaccination and immunization and relevant subheadings was performed. The abstract of each individual article was screened to detect relevant studies, and the reference list of all relevant articles was screened for additional studies.
The resulting articles were then sorted after type leading to 51 included relevant papers. Case reports were omitted. 5 Similar search strategy (replacing MS with ON) was later performed for ON. The same procedure as above resulted in the inclusion of 13 research articles and 2 reviews. Thirty-one case reports were excluded.
| RESULTS
A detailed description of the analyses of the 51 included papers on vaccines and MS, including statistical analyses, is given elsewhere, including a table with a thorough description of each study. In relation to MS onset, there was no increased risk of developing MS after vaccination against HBV, HPV, seasonal influenza and H1N1, MFR, variola, BCG, polio, tetanus, diphtheria, varicella, rabies, pertussis, typhoid fever and cholera. 5 In relation to MS relapses, there was no increased risk of developing MS after vaccination against HBV, tetanus, tick borne encephalitis, seasonal influenza and H1N1. BCG was based on a randomized study of 73 patients presenting with a first demyelinating event followed for 5 years. Therefore, scientific-based evidence is highly needed, which led us to perform a thorough literature survey. The general impression (except for vaccination against yellow fever) is that vaccinations in MS and ON appear safe, neither increasing the risk of development of these diseases nor relapses during MS. However, based on the potentially increased risk of relapses after yellow fever vaccination seen in one study of only 7 patients with relapsing-remitting MS, it is in daily practice recommended to avoid live vaccines, for example against yellow fever, during and in particular shortly after the dosing of secondor third-line treatment of MS 6 . This may limit the patients travelling to risk areas of the relevant infection.
Regarding the potential decreased risk of developing MS if receiving BCG vaccine after the first demyelinating event, the results of a single randomized study (73 patients) was marginally significant (P = .04). 7 Further studies with more cases and an extended follow-up period would be necessary to substantiate the claim of association. It is of notice that none of the 7 case-control studies revealed an association between the BCG vaccine and onset of MS. Thus, more extensive well-designed study techniques limiting the risk of confounding and bias would be necessary to fully exclude a causal association. The clinical material is essential. Established cohorts previously used for other purposes may be ideal. 10 Nested cohort studies with selection from extensive outcome (relapse) data may be optimal.
11
Prospective studies may use at risk-not at risk statistics provided all relapses are identified. 12 The concept of "association" may refer to early effects (within weeks) and long-term effects, and defining that in advance may provide more convincing results. 13 The use of large reporting databases may lead to ascertainment bias, as probably occurred in Geier et al., 14 if the database is not automatically linked to a general quality register. Another future direction would be increase our present knowledge concerning relation of vaccines to disease-modifying drugs by reviewing the increasing amount of pharmacovigilance (and pharmacogenetic) data. The immunosuppressed patients' ability to produce an efficient response to vaccines is of urgent interest.
